Morris Kandinov LLP is representing Camac Fund, LP in an action against the board of directors of Forte Biosciences, Inc. and other defendants who attempted to fix the vote in advance of the company’s annual meeting.
Morris Kandinov LLP is representing an investor in an action against Forte Biosciences Inc.’s board for breaching its fiduciary duties by diluting stockholders’ voting power to protect incumbents’ positions.
After being sued, the board of trustees of the First Trust closed-end funds announced that they have “determined to rescind the control share provisions.”
The Delaware Chancery Court rejected an interlocutory appeal of the Court’s prior ruling denying defendants’ motion to dismiss, permitting discovery to proceed in the case.
Morris Kandinov LLP represents investors in a dispute over a SPAC’s remaining assets in a dissolution after a failed transaction resulted in a termination fee.
Matt Levine writes about the key issue raised by three new SPAC cases filed by Morris Kandinov LLP: “Who gets the cash: the public shareholders, or the sponsors?”